(Q35076967)

6 August 2017

1 reference

title

Current strategies in the prevention of respiratory syncytial virus disease (English)

1 reference

6 August 2017

Paes BA

1

1 reference

PubMed ID

12615029

6 August 2017

language of work or name

1 reference

1 March 2003

1 reference

Paediatric Respiratory Reviews

6 August 2017

1 reference

6 August 2017

4

1 reference

6 August 2017

1

1 reference

6 August 2017

21-27

1 reference

Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus infection in tropical and developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus: changes in prevalence of subgroups A and B among Argentinian children, 1990-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Severity of respiratory syncytial virus infection is related to virus strain

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus infections in infants: Quantitation and duration of shedding

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Possible transmission by fomites of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Modes of transmission of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

A cost-benefit analysis of RSV prophylaxis in high-risk infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2802%2900306-8

7 January 2021

10.1016/S1526-0542(02)00306-8

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12615029